CCL5 and neoplasm: Although both daily and intermittent dosing of BAY1082439 can effectively inhibit PTEN-null prostate tumor cell growth and decrease the number of tumor-associated B cells and Tregs, only intermittent dosing schedule can activate the intratumoral cytotoxic CD8+ T cells, allow them to undergo clonal expansion, and infiltrate into the cancer acini probably via increased CCL5 or CXCL10 secretion (Figs. 2, 3, 4, 6 and 7).